<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924364</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12030255</org_study_id>
    <nct_id>NCT01924364</nct_id>
  </id_info>
  <brief_title>Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using TGI Device</brief_title>
  <acronym>AFIRM-TGI</acronym>
  <official_title>Structural Fat Grafting for Craniofacial Trauma: Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using the Tissue Genesis Cell Isolation System™ (CIS) Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J. Peter Rubin, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this research is to evaluate the physical changes that occur over time
      after fat grafting for craniofacial trauma. This protocol is similar to an existing study
      (IRB# PRO0906101) presently conducted at the University of Pittsburgh by the same research
      team which utilizes fat grafts. The preparation of the fat graft material in each clinical
      trial is processed differently evaluating the effects of graft resorption after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the proposed clinical investigation of the Tissue Genesis Cell
      Isolation System™ (TGI CIS) device constitutes a feasibility study directed at an initial
      evaluation of the device in a certain clinical population, namely subjects undergoing
      craniofacial fat grafting.

        1. Treat disfiguring craniofacial injuries in 5 subjects with fat grafting enhanced with
           adipose stromal vascular fraction (SVF) via TGI 1000 isolation methods to improve form
           with a high level of precision. Facial appearance and persistence of treatment effect
           will be assessed using aesthetic grading scales, state of the art 3-dimensional (3D)
           photography, and high resolution computed tomography (CT) scanning with 3D
           reconstruction. Patients will be followed for 24 months after treatment to define long
           term outcomes.

        2. Assess biologic properties of the cells within the fat graft and correlate with clinical
           outcomes. This will include adipose stem cell yield per volume of fat tissue, cell
           proliferation, capacity for adipogenic differentiation, lipolysis, and cell
           sub-population analysis by multiparameter flow cytometry. Results of these assays will
           be correlated with graft volume retention to search for predictors of good clinical
           outcome that are related to variation on adipose biology between subjects.

        3. Measure quality of life in patients before and after autologous fat grafting using
           validated psychosocial measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2012</start_date>
  <completion_date type="Actual">September 28, 2016</completion_date>
  <primary_completion_date type="Actual">September 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>split-person study in which different parts of the same person may be assigned to receive different interventions, randomization occurs in regards to which site receives TGI or no TGI per site.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Fat Volume Injected and Facial Volume Postop</measure>
    <time_frame>Surgical visit, PO Study visits month 3, month 9, month 12, and month 24</time_frame>
    <description>Facial appearance and persistence of treatment effect will be assessed using high resolution CT scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adipose Stem Cell Yield Per Volume of Fat Tissue</measure>
    <time_frame>Surgical visit</time_frame>
    <description>this describes the biologic properties of the cells within the fat graft</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Facial Injuries</condition>
  <condition>Tissue Injury</condition>
  <arm_group>
    <arm_group_label>Fat grafting with TGI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fat grafting without TGI - Standard of care</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Genesis Cell Isolation System™ (TGI CIS)</intervention_name>
    <description>In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.</description>
    <arm_group_label>Fat grafting with TGI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care fat grafting</intervention_name>
    <description>In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.</description>
    <arm_group_label>Fat grafting without TGI - Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Subjects who are male or female, military or civilian, 18 years of age or older and
             able to provide informed consent

             2. Have suffered injury resulting in craniofacial volume defects which could be
             treated with a graft volume of between 3 and 100 cc of lipoaspirate

             3. Be at least 3 months post-injury or post-surgery (from trauma procedures) so that
             acute edema is resolved

             4. Volume defects are covered by intact skin and do not communicate with oral cavity
             or sinuses

             5. The three dimensional geometry of the volume defects would allow for treatment with
             lipoaspirate injection so that at least two distinct treated areas could be discerned
             on gross examination and radiographically (e.g. treated regions are on opposite sides
             of the face, on lower face versus upper face, or separated by a bony landmark such as
             zygoma. This would include the ability to treat uninjured regions with fat grafts in
             order to obtain symmetry or balance.

             6. Subjects who are, in the opinion of the Investigator, able to understand the study,
             comply with the study design and are willing to return to the clinic for all the
             research required follow-up visits

        Exclusion Criteria:

          -  1. Craniofacial defects intended for treatment have open wounds or communicate with
             oral cavity or sinus (note: presence of such a defect in the setting of another
             defect(s) that meets treatment criteria will not exclude the patient from
             participating).

             2. Active infection anywhere in the body

             3. Diagnosis of cancer within last 12 months and /or actively receiving chemotherapy
             or radiation treatment

             4. Subjects with known idiopathic or drug-associated coagulopathy assessed by
             screening history and physical examination.

             5. Subjects who have, as determined by the investigator a history or clinical
             manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic,
             psychiatric, or other condition that would preclude participation in the study (i.e.
             Type 1 and Type 2 diabetic patients) or any condition within the last 14 days
             requiring hospitalization or surgical intervention.

             6. Subjects who are pregnant, lactating, and women of child-bearing potential who are
             not abstinent or practicing an acceptable means of contraception, as determined by the
             Investigator, for the duration of the treatment phase

             7. Subjects with known alcohol or narcotic drug dependency

             8. Subjects with a history of abnormal blood biochemistry or any other abnormal
             laboratory findings, as defined by the normal value range within the UPMC Laboratory's
             value references and whose values are considered as determined by the investigator to
             be clinically significant, would render the subject inappropriate for the surgical
             procedures (i.e. CBC with Differential, platelets, comprehensive metabolic panel to
             include electrolytes, bun/creatinine, liver function test and coagulation tests).
             Reference to UPMC Laboratory normal value document (Attachment # 18)

             9. Subjects with a life expectancy of &lt;9 months, terminal conditions or factors making
             follow-up difficult (e.g. no fixed address, telephone etc)

             10. Subjects with a known allergy to collagenase, an ingredient used by the TGI CIS to
             process the SVF product.

             11. Subjects with an Axis II to diagnosis DSM-IV (e.g., Schizophrenia, Bipolar
             Disorder). Subjects who are found to be stable on medication and receive psychiatric
             clearance could be eligible for study participation per the Physician's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Peter Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg. 2008 Jan;32(1):48-55; discussion 56-7. Epub 2007 Sep 1.</citation>
    <PMID>17763894</PMID>
  </reference>
  <reference>
    <citation>Zhu M, Zhou Z, Chen Y, Schreiber R, Ransom JT, Fraser JK, Hedrick MH, Pinkernell K, Kuo HC. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg. 2010 Feb;64(2):222-8. doi: 10.1097/SAP.0b013e31819ae05c.</citation>
    <PMID>20098110</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <results_first_submitted>October 4, 2017</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>J. Peter Rubin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Craniomaxillofacial (CMF) Battle-injured (BI)</keyword>
  <keyword>Facial Trauma</keyword>
  <keyword>Fat Grafts</keyword>
  <keyword>Autogenous Fat Transfers (AFT)</keyword>
  <keyword>Wounded warriors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Facial Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>It is the Principal Investigator's intention to make stored samples and subject de-identified information available to secondary investigators after all research study testing has been completed. These stored samples and associated subject information will not include subject identifiers.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fat Grafting</title>
          <description>Same patient received either fat graft treatment supplemented with TGI or no TGI, randomized per site.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fat Grafting</title>
          <description>Tissue Genesis Cell Isolation System™ (CIS): In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) will be used for comparison.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment</title>
          <description>Working full time, part time, unemployed, or retired</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Full time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Part time</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unemployed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Retired</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Smoker, current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Smoker, former</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Fat Volume Injected and Facial Volume Postop</title>
        <description>Facial appearance and persistence of treatment effect will be assessed using high resolution CT scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes.</description>
        <time_frame>Surgical visit, PO Study visits month 3, month 9, month 12, and month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TGI_Fat Volume Injected</title>
          </group>
          <group group_id="O2">
            <title>TGI_Facial Volume at 3 Month PO</title>
            <description>Facial volume at 3 month post-operative</description>
          </group>
          <group group_id="O3">
            <title>TGI_Facial Volume at 9 Month PO</title>
            <description>Facial volume at 9 month PO</description>
          </group>
          <group group_id="O4">
            <title>TGI_Facial Volume at 12 Month PO</title>
            <description>Facial volume at 12 month post-operative</description>
          </group>
          <group group_id="O5">
            <title>TGI_Facial Volume at 24 Month PO</title>
            <description>Facial volume at 24 month PO</description>
          </group>
          <group group_id="O6">
            <title>Standard_Fat Volume Injected</title>
          </group>
          <group group_id="O7">
            <title>Standard_Facial Volume at 3 Month PO</title>
            <description>Standard_Facial volume at 3 month PO</description>
          </group>
          <group group_id="O8">
            <title>Standard_Facial Volume at 9 Month PO</title>
            <description>Facial volume at 9 month PO</description>
          </group>
          <group group_id="O9">
            <title>Standard_Facial Volume at 12 Month PO</title>
            <description>Standard_Facial volume at 12 month PO</description>
          </group>
          <group group_id="O10">
            <title>Standard_Facial Volume at 24 Month PO</title>
            <description>Standard_Facial volume at 24 month PO</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fat Volume Injected and Facial Volume Postop</title>
          <description>Facial appearance and persistence of treatment effect will be assessed using high resolution CT scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="1.4"/>
                    <measurement group_id="O2" value="79.8" spread="14.9"/>
                    <measurement group_id="O3" value="49.6" spread="20.0"/>
                    <measurement group_id="O4" value="52.8" spread="15.5"/>
                    <measurement group_id="O5" value="42.4" spread="28.4"/>
                    <measurement group_id="O6" value="10.1" spread="8.6"/>
                    <measurement group_id="O7" value="86.9" spread="19.5"/>
                    <measurement group_id="O8" value="73.0" spread="25.5"/>
                    <measurement group_id="O9" value="71.9" spread="26.6"/>
                    <measurement group_id="O10" value="62.5" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Stem Cell Yield Per Volume of Fat Tissue</title>
        <description>this describes the biologic properties of the cells within the fat graft</description>
        <time_frame>Surgical visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TGI_Stem Cell Viability Yield</title>
            <description>%age of cells yield/volume of fat tissue</description>
          </group>
          <group group_id="O2">
            <title>Standard_Stem Cell Viability Yield</title>
            <description>%age of cells yield/volume of fat tissue</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Stem Cell Yield Per Volume of Fat Tissue</title>
          <description>this describes the biologic properties of the cells within the fat graft</description>
          <units>%age of cells yield/volume of fat tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.54" spread="8.85"/>
                    <measurement group_id="O2" value="70.48" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fat Grafting</title>
          <description>Tissue Genesis Cell Isolation System™ (TGI CIS): In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>bruising</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Danielle Minteer</name_or_title>
      <organization>University of Pittsburgh Plastic Surgery</organization>
      <phone>412-383-4804</phone>
      <email>minteerdm@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

